CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
24 Abril 2024 - 11:53AM
Business Wire
Please replace the release dated April 23, 2024 with the
following corrected version due to multiple revisions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240423922725/en/
Dr. Robert Geller (Photo: Business
Wire)
The updated release reads:
PHARMAESSENTIA APPOINTS ROBERT GELLER, M.D.
AS HEAD OF MEDICAL
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia
Corporation (TWSE: 6446), a global biopharmaceutical innovator
based in Taiwan leveraging deep expertise and proven scientific
principles to deliver new biologics in hematology and oncology,
today announced the appointment of Robert Geller, M.D. as Head of
Medical.
Dr. Robert Geller is a medical oncologist with diverse expertise
across the biotechnology industry and in academia, including in
drug development, medical affairs, business development and as a
clinical scientist. As the new Head of Medical at PharmaEssentia,
Dr. Geller will be responsible for U.S. clinical operations,
reporting to Chief Medical Officer, Albert Qin, M.D., Ph.D. Most
recently, Dr. Geller was the Chief Medical Officer at Aravive Inc,
where he was responsible for the medical oversight of clinical
trials related to the development of batiraxcept, including a Phase
3 trial in platinum resistant ovarian cancer, as well as safety and
pharmacovigilance. Prior, he served as Senior Vice President,
Medical Affairs at Coherus Biosciences, where he was responsible
for recruiting and reorganizing a Medical Affairs team to support
post marketing of UDENYCA®, and the expansion of the oncology
franchise and ophthalmology and immunology pipelines. Dr. Geller
has also held medical roles at Heron Therapeutics, Alexion
Pharmaceuticals and Vion Pharmaceuticals. His clinical experience
includes serving as Medical Director at several community and
regional cancer centers across the country, as well as Partner in a
specialty oncology/hematology practice. Dr. Geller received his
M.D. from Harvard Medical School/Harvard-MIT Health Science
Technology and an B.S./M.S. in physics from Massachusetts Institute
of Technology.
“I am thrilled to welcome Robert to the PharmaEssentia family to
help advance our commitment to provide new therapeutic solutions
for patients with myeloproliferative neoplasms and other
hematological diseases that have limited therapeutic options,” said
Dr. Ko-Chung Lin, PharmaEssentia CEO. “This is an exciting time in
our Company’s growth, as we continue to establish the clinical
value of ropeginterferon alfa-2b-njft, marketed as BESREMi®, for
myeloproliferative neoplasms and to advance our pipeline; we look
forward to Robert’s leadership and partnership with our physician
and patient communities.”
UDENYCA is a registered trademark of Coherus Biosciences,
Inc.
About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in Taipei, Taiwan, is
a global and rapidly growing biopharmaceutical innovator.
Leveraging deep expertise and proven scientific principles,
PharmaEssentia aims to deliver effective new biologics for
challenging diseases in the areas of hematology, oncology, and
immunology with one approved product and a diversifying pipeline.
Founded in 2003 by a team of Taiwanese-American executives and
renowned scientists from U.S. biotechnology and pharmaceutical
companies, today PharmaEssentia is expanding its global presence
with operations in the U.S., Japan, China, and Korea, along with a
world-class biologics production facility in Taichung, Taiwan.
For more information about PharmaEssentia USA, visit the
website, LinkedIn or Twitter.
Forward Looking Statement
This press release may contain forward looking statements,
including statements regarding the clinical benefits to be derived
from ropeginterferon alfa-2b, the commercial opportunity and
competitive positioning, new indications or labeling for
ropeginterferon alfa-2b, and business prospects for ropeginterferon
alfa-2b. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and similar legislation
and regulations under Taiwanese law. These forward-looking
statements are based on management expectations and assumptions as
of the date of this press release, and actual results may differ
materially from those in these forward looking statements as a
result of various factors. These factors include whether BESREMi is
successfully commercialized and adopted by physicians and patients,
the extent to which reimbursement is available for BESREMi, and the
ability to receive FDA and other regulatory approvals for
additional indications for BESREMi. We do not undertake to update
any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.
© 2024 PharmaEssentia Corporation. All rights reserved.
PharmaEssentia, the PharmaEssentia logo, and BESREMi are
trademarks or registered trademarks of PharmaEssentia
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423922725/en/
Media: Muriel Huang, muriel_huang@pharmaessentia.com